Seres Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$7.52next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 10 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly29.8M
Quarterly Research and Development (R&D) Expenses Quarterly13.2M
Quarterly General and Administrative (G&A) Expenses Quarterly8.1M
Watch Items
- SER-155 clinical data readout in immune checkpoint inhibitor-related enterocolitis (irEC)Trigger: Initial clinical efficacy and safety data from the 15-subject investigator-sponsored trial at Memorial Sloan Kettering Cancer CenterAction: Evaluate potential development pathways, adjacent expansion opportunities, and strategic partnerships based on the clinical results.
- Funding and partnerships for SER-155 Phase 2 study in allo-HSCTTrigger: Securing external funding or a strategic co-development partner to initiate the paused Phase 2 clinical trialAction: Resume preparatory and clinical startup activities for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplantation.
- IND-enabling progress for SER-603 in inflammatory bowel disease (IBD)Trigger: Completion of IND-enabling studies and submission of Investigational New Drug application to the FDAAction: Initiate Phase 1 clinical development for SER-603 to target gastrointestinal microbiome disruptions and mucosal healing.
Research as of 20 Jun 2026